MedTrace Logo

MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine

NCT05197751 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2023-02-28

No results posted yet for this study

Summary

First-in-Human, Randomised, Dose-Finding Single Center Study to evaluate three dose levels of a novel malaria vaccine, MSP3-CRM-Vac4All/ Alhydrogel® : 3 µg, 10 µg and 30 µg

Conditions

  • Malaria,Falciparum

Interventions

BIOLOGICAL

MSP3-CRM-Vac4All/ Alhydrogel®

The Investigational Medicinal Product (IMP) or in short Investigational Product (IP) is the MSP3-CRM-Vac4All/ Alhydrogel® vaccine

Sponsors & Collaborators

  • Vac4All

    lead INDUSTRY

Principal Investigators

  • Mahamadou Thera, MD · MRTC, University of Sciences Techniques and Technologies of Bamako, Mali

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-08-03
Completion
2023-05-09

Countries

  • Mali

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05197751 on ClinicalTrials.gov